Anika Therapeutics | ANIK - Debt


Anika Therapeutics reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Abbott USD 12.94B 496M Sep/2025
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.89M 163.33M Dec/2025
Integra LifeSciences USD 2.01B 7.91M Sep/2025
Intrexon USD 0 13.82M Jun/2024
J&J USD 47.93B 2.14B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
Merit Medical Systems USD 821.15M 599K Sep/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 21.76B 530M Sep/2025
Smith & Nephew USD 3.32B 334M Dec/2024
Stryker USD 14.86B 1.74B Dec/2025
Surmodics USD 29.55M 111K Sep/2024
Veracyte USD 40.45M 10.19M Sep/2025
Xencor USD 69.27M 1.34M Sep/2025
Zimmer Biomet Holdings USD 7.52B 593.5M Dec/2025